midazolam + phenobarbital + propofol

This is a combination of three sedative-hypnotic drugs—midazolam, phenobarbital, and propofol—used for deep sedation or anesthesia in critical care and procedural settings. - **Midazolam** is a short-acting benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, producing anxiolytic, amnestic, muscle relaxant, and sedative effects[8][10]. - **Phenobarbital** is a long-acting barbiturate that enhances GABAergic inhibition by prolonging the opening of chloride channels at the GABA-A receptor; it is used for long-term sedation and seizure control[2][4]. - **Propofol** is an intravenous anesthetic agent with rapid onset and short duration of action; it also acts as a positive allosteric modulator at the GABA-A receptor and inhibits certain sodium channels[7]. The combination may be considered in refractory cases requiring profound sedation (e.g., status epilepticus unresponsive to standard therapy), though such triple regimens are rare due to risk of cumulative CNS depression. Each drug potentiates inhibitory neurotransmission via distinct but overlapping mechanisms on the GABA-A receptor complex. The use of multiple agents can allow dose reduction for each component through synergistic effects but increases monitoring requirements due to additive risks (e.g., respiratory depression, hypotension)[3][5][6].